Pharma company to pay $95 million in settlement for 'off-label' drug promotion

Share this article:

A pharmaceutical company will pay $95 million over allegations of kickbacks regarding three medications used in skilled nursing facilities and hospitals.

Boehringer Ingelheim Pharmaceuticals manufactured the drugs: Aggrenox, used to prevent strokes; Combivent, used to treat Chronic Obstructive Pulmonary Disease; and Micardis, used to treat high blood pressure. The Department of Justice says Boehringer engaged in “off-label marketing” of the drugs.

The Food and Drug Administration has approved Aggrenox to prevent secondary strokes, Combivent to treat symptoms of bronchospasm in patients with COPD who already are on a bronchodilator, and Micardis to treat hypertension, the Department of Justice said.

The federal share of the civil settlement is more than $78 million; and the state Medicaid share is $16.5 million. The case was brought by a whistleblower in Maryland under the False Claims Act. That individual will receive $17 million from the federal share of the civil recovery.

The settlement reflects an increased interest of state and federal government in examining pharmaceutical companies and pharmacies distributing drugs for off-label use.

Share this article:

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.